Zimbabwe has turned down a significant US health deal worth 367 million US dollars (272 million pounds) spanning five years due to Washington's request for confidential biological samples.
This rejection came to light following a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesman later stated that the US was demanding access to genetic material for research and commercial gain while was not willing to guarantee the benefits from any future vaccines.
"We are forced to start the difficult and regrettable process of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for further negotiations to find a agreement suitable to both sides so the nation's vital HIV treatment initiative can proceed.
Wider Background
This rejection comes after a comparable situation in Kenya, where a high court suspended a related health funding agreement following legal challenges were filed about the safety of Kenyans' health data.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral deals to boost openness and accountability.
According to statements, 16 nations in Africa have to date signed these new agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any corresponding promise of benefiting from any scientific breakthroughs – like new medicines or tests – that could result from that provided information," Mangwana explained.
"Effectively, our country would supply the basic resources for scientific discovery with no certainty that the end products would be accessible to our citizens should a future health crisis emerge."
National Interest and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were undermining structures previously set up through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to manage future global health emergencies.
"This framework is designed to guarantee that when a country contributes its samples, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome continued discussions with our US partners on how subsequent co-operation could be designed in a way that honours the independence and interests of each country."
Medical Community Response
A leading public health body stated it recognised the government's concerns, but suggested that negotiations need to persist given that much of the nation's Aids initiatives relied on foreign aid.
"Where technical issues exist, including those involving data governance or implementation frameworks, these can often be addressed via detailed discussion and negotiated safeguards," the group added.
The halted deal highlights the complex debate between accepting crucial international aid and protecting a country's data in an increasingly interconnected world.